Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
| ▸ | APOL1 | O14791 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 7/20 | 0.32 |
| ▸ | FPR1 | P21462 | 6/20 | 0.31 |
| ▸ | RAMP1 | O60894 | 3/20 | 0.31 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16653213 | 1.00 | HCRTR2 (0.32) | HCRTR2APOL1FPR2FPR1RAMP1 | |
| SCHEMBL35210112 | 0.84 | GAA (0.44) | EPHX2 | |
| SCHEMBL20664223 | 0.84 | GAA (0.44) | EPHX2 | |
| SCHEMBL15280651 | 0.84 | GAA (0.44) | EPHX2 | |
| SCHEMBL35210100 | 0.84 | GAA (0.44) | EPHX2 | |
| SCHEMBL15280630 | 0.84 | GAA (0.44) | EPHX2 | |
| SCHEMBL16652961 | 0.78 | HCAR2 (0.37) | HCRTR2APOL1RAMP1CALCRL | |
| SCHEMBL16652791 | 0.78 | SMN1; SMN2 (0.44) | EPHX2 | |
| SCHEMBL3709136 | 0.78 | SMN1; SMN2 (0.44) | EPHX2 | |
| SCHEMBL3711887 | 0.77 | SLC6A3 (0.41) | FPR2FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2849568-B1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3430906-A1 | CRYSTALLINE FORMS OF CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2019-01-23 | — | — | EP | disclosed |
| US-10106541-B2 | Intermediates for preparing CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180127417-A1 | INTERMEDIATES FOR PREPARING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9487523-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9174989-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150112067-A1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106541-B2 | Intermediates for preparing CGRP receptor antagonists | CALCR, CALCRL, VIPR1 | HCRTR2 138/4885APOL1 4614/4885FPR2 713/4885 |
| US-20180127417-A1 | INTERMEDIATES FOR PREPARING CGRP RECEPTOR ANTAGONISTS | CALCR, CALCRL, VIPR1 | HCRTR2 138/4885APOL1 4614/4885FPR2 713/4885 |
| US-20150112067-A1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | CCKBR, BDKRB2, CALCR | HCRTR2 167/4885APOL1 4767/4885FPR2 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.